-
1.发明申请
公开(公告)号：WO2023092089A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/080167
申请日：2022-11-18
Inventor： KIM, HoWon J. , KIM, In-San , KIM, Jay S. , KIM, Sun Hwa , KWON, Ick Chan , LEE, Jong Won , YANG, Yoo Soo , YOON, Hong Yeol
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.
-
公开(公告)号：WO2023006919A1
公开(公告)日：2023-02-02
申请号：PCT/EP2022/071275
申请日：2022-07-28
Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , CENTRE LEON BERARD , UNIVERSITÉ CLAUDE BERNARD LYON 1 , KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY)
Inventor： HENNINO, Ana
Abstract: The tumoral stroma evolution during cancer is playing a key role as it may acts as a physical barrier limiting access of the immune cells to the tumor. Thus, βig-h3 (TGFβi) overexpression in the stroma is of bad prognosis in Pancreatic Ductal Adenocarcinoma and in other cancers. A monoclonal antibody against βig-h3 protein called 18B3 was shown playing a role in directly modulating the anti-tumoral immune response by blocking inhibiting CD8+ T cell activation. From 18B3 the inventors developed humanized antibodies having unexpectedly high affinity, slow dissociation rate and strong thermal stability making them powerful candidates for treating cancers wherein the stroma expresses βig-h3 in vivo. The invention thus relates to these humanized monoclonal antibodies and methods of treatment of such cancers.
-
公开(公告)号：US20250122508A1
公开(公告)日：2025-04-17
申请号：US18982078
申请日：2024-12-16
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis.
-
4.发明公开公开(公告)号：US20240325550A1
公开(公告)日：2024-10-03
申请号：US18618258
申请日：2024-03-27
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: A61K47/64 , A61P35/00 , C12N15/113
CPC classification number: A61K47/64 , A61P35/00 , C12N15/113 , C12N2310/14 , C12N2310/141
Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.
-
5.发明申请Internal reforming molten carbonate fuel cell with membrane for intercepting carbonate vapor 失效内部重整熔融碳酸盐燃料电池与膜截留碳酸盐蒸气公开(公告)号：US20010026881A1
公开(公告)日：2001-10-04
申请号：US09761869
申请日：2001-01-16
Inventor： Tae Hoon Lim , Heung Yong Ha , Suk Woo Nam , In Hwan Oh , Seong Ahn Hong , Hyeung Dae Moon , Ho In Lee
IPC: H01M008/14 , H01M008/06
CPC classification number: H01M8/0625 , H01M2008/147 , H01M2300/0051 , Y02E60/526
Abstract: An internal reforming molten carbonate fuel cell having a membrane for intercepting carbonate vapor and hydrated vapor is disclosed. The intercepting membrane is made from nickel or nickel alloy which has a high electrical conductivity, corrosion resistant property in an anode environment, and a low affinity for the carbonate vapor. Due to the presence of the intercepting membrane, the transfer of the carbonate vapors and hydrated vapors to the internal reforming catalyst is markedly retarded to prolong the catalytic activity. As a result, a longer operating molten carbonate fuel cell can be obtained.
Abstract translation: 公开了一种具有用于截留碳酸盐蒸汽和水合蒸汽的膜的内部重整熔融碳酸盐燃料电池。 拦截膜由镍或镍合金制成，其在阳极环境中具有高导电性，耐腐蚀性，并且对碳酸盐蒸气的亲和力低。 由于截留膜的存在，碳酸盐蒸气和水化蒸气向内部重整催化剂的转移显着延迟以延长催化活性。 结果，可以获得更长的操作熔融碳酸盐燃料电池。
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240360457A1
公开(公告)日：2024-10-31
申请号：US18765587
申请日：2024-07-08
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the cancer cell via endocytosis.
-
7.发明公开公开(公告)号：US20240150771A1
公开(公告)日：2024-05-09
申请号：US18407815
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.
-
公开(公告)号：US12140594B2
公开(公告)日：2024-11-12
申请号：US18348398
申请日：2023-07-07
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Centre National de la Recherche Scientifique (CNRS) , Universite Claude Bernard—Lyon 1 , Centre Leon Berard , KIST (Korea Institute of Science and Technology)
Inventor： Kim In-San , Philippe Bertolino , Ana Hennino
IPC: G01N31/00 , G01N33/53 , G01N33/574
Abstract: The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of βig-h3 protein in a blood sample wherein the serum level of βig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that βig-h3 can be directly detected in the blood sample and βig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of βig-h3 protein, for use in the treatment of PDAC. The inventors found that βig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing βig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response. Thus, neutralizing βig-h3 which acts as a novel immunological check-point target in PDAC therefore allows to restore beneficial anti-tumor immunity in PDAC.
-
9.发明公开公开(公告)号：US20240191237A1
公开(公告)日：2024-06-13
申请号：US18407780
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.
-
公开(公告)号：US20240159759A1
公开(公告)日：2024-05-16
申请号：US18348398
申请日：2023-07-07
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Centre National de la Recherche Scientifique (CNRS) , Universite Claude Bernard - Lyon 1 , Centre Leon Berard , KIST (Korea Institute of Science and Technology)
Inventor： Kim IN-SAN , Philippe BERTOLINO , Ana HENNINO
IPC: G01N33/574
CPC classification number: G01N33/57438
Abstract: The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of βig-h3 protein in a blood sample wherein the serum level of βig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that βig-h3 can be directly detected in the blood sample and βig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of βig-h3 protein, for use in the treatment of PDAC. The inventors found that βig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing βig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response. Thus, neutralizing βig-h3 which acts as a novel immunological check-point target in PDAC therefore allows to restore beneficial anti-tumor immunity in PDAC.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.031 seconds)
